Publication Topic: Adrenal Imaging

Abstract/Summary:

It is well established that changes in fluid and electrolyte homeostasis may accompany and are likely to modify the clinical symptoms of alcohol withdrawal reactions. It was of obvious theoretical and practical interest, therefore, to investigate the changes in the secretion of hormones which regulate the fluid and electrolyte homeostasis [α-atrial natriuretic peptide (α-ANP), aldosterone (ALDO) and plasma renin activity (PRA)], together with the changes in the serum electrolytes (sodium, potassium) in male chronic alcoholic inpatients. The patients were transferred to the hospital because of severe alcohol withdrawal reactions. Blood samples were taken on Day 1 (severe withdrawal) and Day 10 (partial recovery from withdrawal) of hospitalization. The peptide and steroid hormones were measured with RIA (radioimmunoassay), while flame photometry was used to measure the electrolytes in the serum. At the time of hospital admission, there was an increased PRA and ALDO level observed. Ten days later, the elevated PRA and ALDO levels were greatly reduced and thus they were back to the normal range. In 60% of the patients, delirium tremens has gradually developed during the observation period. In these patients, an elevated level of α-ANP was observed at the time of hospital admission, i.e., days before actual onset of delirium tremens. It is concluded that the disturbed volume homeostasis and the consequently altered α-ANP secretion might be associated with and therefore used as an indicator of the onset of delirium tremens.

Authors: Attila Bezzegh, László Nyuli, Gábor L. Kovács
Keywords: alcohol withdrawal reactions, delirium tremens
DOI Number: 10.1016/0741-8329(91)90513-V
Publication Year: 1991

Abstract/Summary:

Primary aldosteronism (PA) is the most common form of endocrine hypertension and effects one in 50 adults. PA is characterized by inappropriately elevated aldosterone production via renin-independent mechanisms. Driver somatic mutations for aldosterone excess have been found in approximately 90% of aldosterone-producing adenomas (APAs). Using next-generation sequencing, we identified recurrent in-frame deletions in SLC30A1 in five APAs (p.L51_A57del, n=3; p.L49_L55del, n=2). SLC30A1 encodes the ubiquitous zinc efflux transporter ZnT1 (zinc transporter 1). The identified SLC30A1 variants are situated in close proximity of the zincbinding site (H43 and D47) in transmembrane domain II and likely cause abnormal ion transport. PA cases with the unique SLC30A1 mutations showed male dominance and demonstrated increased aldosterone and 18-oxo-cortisol concentrations. Functional studies of the mutant SLC30A151_57del variant in a doxycycline-inducible adrenal cell system revealed abnormal Na+ conductivity caused by the mutant, which in turn led to the depolarization of the resting membrane potential, and thus to the opening of voltage-gated calcium channels. This resulted in an increase in cytosolic Ca2+ activity, which stimulated CYP11B2 mRNA expression and aldosterone production. Collectively, these data implicate the first-in-field zinc transporter mutations as a dominant driver of aldosterone excess in PA.

Authors: Juilee Rege, Kazutaka Nanba, Sascha Bandulik, Carla Kosmann, Amy R. Blinder, Pankaj Vats, Chandan Kumar-Sinha, Antonio M. Lerario, Tobias Else, Yuto Yamazaki, Fumitoshi Satoh, Hironobu Sasano, Thomas J. Giordano, Tracy Ann Williams, Martin Reincke, Adina F. Turcu, Aaron M. Udager, Richard Warth, William E. Rainey
Keywords: somatic mutation, SLC30A1, zinc efflux transporter, ZnT1
DOI Number: 10.1101/2022.07.25.501443
Publication Year: 2022

Abstract/Summary:

Primary aldosteronism (PA) describes the most frequent cause of secondary arterial hypertension. Recently, deterioration of lipid metabolism after adrenalectomy (ADX) for aldosterone-producing adenoma (APA) has been described. We analyzed longitudinal changes in lipid profiles in a large prospective cohort of PA patients. Data of 215 consecutive PA patients with APA (n = 144) or bilateral idiopathic adrenal hyperplasia (IHA, n = 71) were extracted from the database of the German Conn’s Registry. Patients were investigated before and 1 year after successful treatment by ADX or by mineralocorticoid receptor antagonists (MRA). Glomerular filtration rate (GFR), fasting plasma glucose and components of lipid metabolism including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were determined at 8.00 after a 12-h fasting period. One year after initiation of treatment mean serum potassium levels and blood pressure normalized in the patients. HDL-C and TG developed inversely with decreasing HDL-C levels in patients with APA (p = .046) and IHA (p = .004) and increasing TG levels (APA p = .000; IHA p = .020). BMI remained unchanged and fasting plasma glucose improved in patients with APA (p = .004). Furthermore, there was a significant decrease of GFR in both subgroups at follow-up (p = .000). Changes in HDL-C and TG correlated with decrease in GFR in multivariate analysis (p = .024). Treatment of PA is associated with a deterioration of lipid parameters despite stable BMI and improved fasting plasma glucose and blood pressure. This effect can be explained by renal dysfunction following ADX or MRA therapy.

Authors: Christian Adolf, Evelyn Asbach, Anna Stephanie Dietz, Katharina Lang, Stefanie Hahner, Marcus Quinkler, Lars Christian Rump, Martin Bidlingmaier, Marcus Treitl, Roland Ladurner, Felix Beuschlein, Martin Reincke
Keywords: aldosterone, glomerular hyperfiltration, lipid metabolism, adrenalectomy, triglycerides, cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, mineralocorticoid receptor antagonists
DOI Number: 10.1007/s12020-016-0983-9
Publication Year: 2016

Abstract/Summary:

There are mounting data that at least 30% of hypertensives who are appropriately screened have primary aldosteronism (PA), rather than the commonly reported figure of 5% to 10%. Second, there are similar data that undertreated patients with PA have a 3-fold higher risk profile than essential hypertensives with the same blood pressure levels. Third, clinicians managing hypertension measure success as sustainable lowering of blood pressure; untreated hypertensive patients with PA are thus in double jeopardy. Finally, and crucially, fewer than 1% of patients with hypertension are ever screened—let alone investigated—for PA. Accordingly, for “Who should we screen?” the answer is simple—all patients with hypertension. For “How they should be screened?” the answer is also simple—add spironolactone 25 mg/day for 4 weeks and measure the blood pressure response. In established hypertension, a fall of <10 mm Hg means PA is unlikely; above 12 mm Hg PA, it is probable. Newly presenting hypertension is much the same—hold off on first-order antihypertensive(s) and prescribe spironolactone 25 mg/day for 4 weeks. If blood pressure falls into the normal range, continue; if it does not, prescribe a standard antihypertensive. It is likely that the above protocols—a first start, amenable to refinement—will find additional hypertensives with unilateral PA; it is probable that the overwhelming majority will have bilateral disease. What this means is that we have a major public health issue on our hands: how can this be the case?

Authors: John W. Funder
Keywords: prevalence
DOI Number: 10.1161/HYPERTENSIONAHA.123.20536
Publication Year: 2023

Abstract/Summary:

Recent genome-wide analyses have found 50 loci associated with variation in blood pressure but failed to advance understanding of the molecular basis of hypertension. Whether hypertension is not after all due to multiple common variants or is simply an order of magnitude more complex than previously suspected remains unsettled – in part because only a minority of subjects in the analyses had true hypertension. A better starting point than normotensive subjects for explaining hypertension may be the most common distinct cause of hypertension, primary hyperaldosteronism (PHA). The findings that 40% of patients with an aldosterone-producing adenoma (APA) of the adrenal have somatic gain-of-function mutations in a single gene, KCNJ5, and that this gene is, less frequently, mutated in inherited cases of PHA, potentially transform the understanding and management of hypertension. Firstly, they illustrate how hypertension could be due to a multiplicity of uncommon variants. Mutations that present with abnormal electrolytes and anatomy are the easiest to detect but are likely the tip of the iceberg. Secondly, we found a genotype:phenotype pattern, with KCNJ5 mutations inducing larger APAs in the cortisol-secreting zona fasciculata in young women. Smaller APAs without KCNJ5 mutations usually present in older men with resistant hypertension, having been overlooked earlier because of their size. This reflects their compact zona glomerulosa cells. Routine measurement of plasma renin in hypertension and a new positron emission tomography/computerized tomography allow prompt diagnosis and management of PHA before resistant hypertension ensues. Wider recognition of distinct phenotypes should permit earlier, specific treatment and reduce life-time risk of complications.

Authors: Morris J Brown
Keywords: aldosteronism genetics, somatic mutations in APAs
DOI Number: 10.1258/cvd.2012.012020
Publication Year: 2012

Abstract/Summary:

Available evidence demonstrates a crosstalk between the renin–angiotensin and the parathyroid hormone–vitamin D systems. A new study suggests that vitamin D supplementation can lower systolic blood pressure and plasma aldosterone levels in patients with primary aldosteronism.

Authors: Gian Paolo Rossi, Livia Lenzini
Keywords: Vitamin D, hyperparathyroidism
DOI Number: 10.1038/s41574-020-0359-3
Publication Year: 2020